Latest News from NPR

on:

NCPR is supported by:

 
Hourly Newscast
4 min., 45 sec.

Programs

Latest program rundown

Coming up:

Latest Features:
September 1, 2014 | NPR · A Guinean student in the Senegalese capital of Dakar has tested positive for the deadly disease. David Greene talks to Krista Larson, West Africa correspondent for the Associated Press.
 
September 1, 2014 | NPR · Protesters surrounded Prime Minister Nawaz Sharif's home, and for a brief period forced government TV off the air. Steve Inskeep talks to Jon Boone, a correspondent for The Guardian in Islamabad.
 
YouTube
September 1, 2014 | NPR · A widely watched video shows a foreigner fainting on a subway car and everyone around him fleeing. No one helps. It's rekindled a national debate about trust, fear and the Chinese national character.
 

Latest program rundown

Coming up:

Latest Features:
September 1, 2014 | NPR · Ebola has exposed weaknesses in Africa's health networks and a failure to work together to arrest the spread of the virus. The "not our problem" response is taking an economic toll on the continent.
 
September 1, 2014 | NPR · Nearly 260 health workers in West Africa have been infected, and 134 have died. Dr. Robert Garry of Tulane University, who worked with five who died, discusses the devastation in the community.
 
YouTube
September 1, 2014 | NPR · Ads with candidates shooting guns are proliferating this year. It can all be traced back to Sen. Joe Manchin's famed 2010 spot "Dead Aim."
 

Latest Saturday rundown




WE Saturday Feature

August 30, 2014 | NPR · Ukrainian forces are defending the port city of Novoazovsk from what they say is a Russian invasion. Scott Simon talks to correspondent Soraya Sarhaddi Nelson.
 

Latest Sunday rundown


WE Sunday Feature

August 31, 2014 | NPR · Immigration remains one of the most challenging issues for President Obama. Political correspondent Mara Liasson discusses the political cost of the choices before him with Linda Wertheimer.
 

Latest program rundown

Coming up:

Avastin

Apr 4, 2012 — U.S. medical practices bought counterfeit medicine labeled as Altuzan from a foreign supplier, the FDA says. Altuzan, which is the Turkish brand name for the blockbuster drug Avastin, is approved for use in Turkey but not in this country.
Comments |
Feb 15, 2012 — Counterfeit versions of diet drugs, Lipitor and a flu medication called Tamiflu have been found in this country before. But so far fake cancer medicines have been rare.
Comments |
Dec 29, 2011 — Avastin slowed the progression of the cancers a bit, but two studies didn't find the drug improved survival overall. Patients getting Avastin as part of treatment with several medicines had more side effects, including blood clots and high blood pressure, than the people who didn't get it.
Comments |
Nov 18, 2011 — After more than a year of deliberations and an unprecedented public hearing in June, the agency has revoked approval of the biotech blockbuster Avastin, a medicine that chokes off the blood supply to various cancer cells, as a treatment for metastatic breast cancer.
Comments |
Oct 13, 2011 — A cancer specialist on an expert panel that voted against keeping Avastin's approval for breast cancer intact explained his decision. He couldn't imagine recommending a drug that only limits progression of cancer without lengthening patient's lives or their quality of life.
Comments |
Jun 30, 2011 — The European Commission gave the OK to an expansion of Avastin's approval to include using the drug in combination with Xeloda, a chemotherapy medicine, to treat metastatic breast cancer.
Comments |
Jun 29, 2011 — Genentech failed to persuade a single member of the Food and Drug Administration's panel of cancer experts that its blockbuster drug Avastin should keep the agency's seal of approval for treating advanced breast cancer.
Comments |
Jun 29, 2011 — In a controversial 2008 decision, the FDA gave fast-track approval for Avastin for breast cancer treatment based on a single study. Now, after subsequent research proved disappointing, a panel has recommended that the agency revoke approval, angering patients and the drugmaker.
Comments |
Apr 29, 2011 — Medicare could save millions if patients with macular degeneration switch to a $50 cancer drug that's just as effective as a $2,000 drug approved for the eye disease. But it was a long haul to get the clinical trial done to prove it.
Comments |
more Avastin from NPR